Amlodipine

1. Front Matter

   Pages I-XV

   PDF

2. The Calcium Antagonists: Are Different Drugs Needed?

   • Winifred G. Nayler

   Pages 1-6

3. Calcium and Its Relevance to Biological Systems

   • Winifred G. Nayler

   Pages 7-14

4. Cell Membrane Transport

   • Winifred G. Nayler

   Pages 15-22

5. The Voltage-Activated, Calcium Antagonist-Sensitive Calcium Channels: Their Structure, Composition and Calcium Antagonist Binding Sites

   • Winifred G. Nayler

   Pages 23-35

6. The Chemistry of the Calcium Antagonists

   • Winifred G. Nayler

   Pages 36-44

7. Amlodipine — A Long-Acting Second Generation Calcium Antagonist with an Unusual Binding Profile

   • Winifred G. Nayler

   Pages 45-60

8. The Pharmacokinetic Properties of Amlodipine

   • Winifred G. Nayler

   Pages 61-72

9. The Vascular Selectivity of Amlodipine

   • Winifred G. Nayler

   Pages 73-88

10. Conditions which Affect the Pharmacokinetic Profile of Amlodipine

    • Winifred G. Nayler

    Pages 89-99

11. Calcium Antagonists and the Kidney

    • Winifred G. Nayler

    Pages 100-110

12. Calcium Antagonism and the Ischaemic Heart: Is Calcium Antagonism Relevant?

    • Winifred G. Nayler

    Pages 111-130

13. Calcium Antagonists and the Stunned Heart — Are Vascular Selective Antagonists Protective?

    • Winifred G. Nayler

    Pages 131-141

14. Amlodipine and the Hibernating Myocardium: Could It Be Beneficial?

    • Winifred G. Nayler

    Pages 142-147

15. Calcium Antagonists and the Treatment of Hypertension

    • Winifred G. Nayler

    Pages 148-177

16. The Antiatherogenic Potential of the Calcium Antagonists, Including Amlodipine

    • Winifred G. Nayler

    Pages 178-198

17. Amlodipine and the Coronary Circulation: Is it a Useful Antianginal Agent?

    • Winifred G. Nayler

    Pages 199-212

18. Calcium Antagonists and Heart Failure

    • Winifred G. Nayler

    Pages 213-226

19. The Side-Effects of Calcium Antagonist Therapy. Is Amlodipine Different?

    • Winifred G. Nayler

    Pages 227-239

20. The Future of Calcium Antagonism

    • Winifred G. Nayler

    Pages 240-241

"Those who choose to increase their knowledge still further by reading ... will discover an exciting new world. " NOEL WHITTAKER, in "Making Money Made Simple" 1989. The development of calcium antagonists has recently been described as representing "one of the major advances in cardiovascular thera­ peutics of the latter half of the twentieth century" (Braunwald, 1990). However, although the development of these drugs started in the mid­ nineteen sixties it is only recently that their real potential has begun to be appreciated. Even now the calcium antagonist saga is not complete, since new compounds continue to appear and new therapeutic applica­ tions emerge. Based on the experience gained in the clinics in which these drugs have been used recognition is being given now to the need to improve upon the prototypes of the group. Such improvement is resulting in the development and production not only of long-acting formulations of the prototypes (nifedipine, verapamil and diltiazem) but also of new calcium antagonists with improved tissue selectivity, potency and duration of action. To those of us who are interested in this field such a development is both exciting and rewarding. As far as the clinicians who prescribe these drugs are concerned the long-acting nature of some of the newer calcium antagonists should make the satisfactory management of their patients an achievable goal.

• Ca++-channel
• Calcium-antagonist
• PTCA
• cardiovascular
• hypertension

• Department of Medicine, Austin Hospital, The University of Melbourne, Heidelberg, Australia

  Winifred G. Nayler

Policies and ethics